The dogma of Cetuximab and Radiotherapy in head and neck cancer - A dawn to dusk journey
Standard
The dogma of Cetuximab and Radiotherapy in head and neck cancer - A dawn to dusk journey. / Krishnamurthy, Sapna; Ahmed, Imtiaz; Bhise, Rohan; Mohanti, Bidhu K; Sharma, Atul; Rieckmann, Thorsten; Paterson, Claire; Bonomo, Pierluigi.
in: CLIN TRANSL RAD ONCO, Jahrgang 34, 05.2022, S. 75-81.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The dogma of Cetuximab and Radiotherapy in head and neck cancer - A dawn to dusk journey
AU - Krishnamurthy, Sapna
AU - Ahmed, Imtiaz
AU - Bhise, Rohan
AU - Mohanti, Bidhu K
AU - Sharma, Atul
AU - Rieckmann, Thorsten
AU - Paterson, Claire
AU - Bonomo, Pierluigi
N1 - © 2022 Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.
PY - 2022/5
Y1 - 2022/5
N2 - Since the introduction of Cetuximab as a biological molecule against Epidermal Growth Factor Receptor (EGFR), its use in the cancers of head and neck region is widely explored. With the recognition that EGFR expression is associated with radioresistance and poor prognosis, incorporation of an anti-EGFR agent along with Radiotherapy (RT) is a logical and attractive option. Cetuximab in combination with RT as Bio-Radiotherapy (BRT) is considered one of the standard treatment modalities in Locally Advanced Head and Neck Squamous Cell Cancers (LA-HNSCC). Many important phase-III clinical trials were undertaken simultaneously, where the use of Cetuximab BRT was tested in various clinical scenarios with different hypothesis. With the studies still ongoing and the results awaited, its use was continued in clinical practice. Today the results are out and definitely not encouraging. After the initial success, Cetuximab has miserably failed to win over cisplatin based chemoradiation which is the current standard of care in LA-HNSCC. Hence, it is the need of the hour to re-evaluate and define the present role of Cetuximab in the definitive management of LA-HNSCC in the light of the latest clinical evidence..
AB - Since the introduction of Cetuximab as a biological molecule against Epidermal Growth Factor Receptor (EGFR), its use in the cancers of head and neck region is widely explored. With the recognition that EGFR expression is associated with radioresistance and poor prognosis, incorporation of an anti-EGFR agent along with Radiotherapy (RT) is a logical and attractive option. Cetuximab in combination with RT as Bio-Radiotherapy (BRT) is considered one of the standard treatment modalities in Locally Advanced Head and Neck Squamous Cell Cancers (LA-HNSCC). Many important phase-III clinical trials were undertaken simultaneously, where the use of Cetuximab BRT was tested in various clinical scenarios with different hypothesis. With the studies still ongoing and the results awaited, its use was continued in clinical practice. Today the results are out and definitely not encouraging. After the initial success, Cetuximab has miserably failed to win over cisplatin based chemoradiation which is the current standard of care in LA-HNSCC. Hence, it is the need of the hour to re-evaluate and define the present role of Cetuximab in the definitive management of LA-HNSCC in the light of the latest clinical evidence..
U2 - 10.1016/j.ctro.2022.03.009
DO - 10.1016/j.ctro.2022.03.009
M3 - SCORING: Review article
C2 - 35356388
VL - 34
SP - 75
EP - 81
JO - CLIN TRANSL RAD ONCO
JF - CLIN TRANSL RAD ONCO
SN - 2405-6308
ER -
